Author

Xuelian Bai

Institution: Junshi Biosciences (China)

Observed institutions: Central South University, Xiangya Hospital Central South University, Junshi Biosciences (China)

ORCID: 0000-0002-6989-6699

Observed ORCID: 0000-0002-6989-6699

OpenAlex ID: A5004073608

Efficacy and Safety of Ongericimab in Chinese Patients With Primary Hypercholesterolemia and Mixed Dyslipidemia

2024 · Xiaozeng Wang, Miaohan Qiu, et al. · Journal of the American Heart Association · 19

SOCS3 participates in cholinergic pathway regulation of synovitis in rheumatoid arthritis

2017 · Tong Li, Shiyao Wu, et al. · Connective Tissue Research · 12

GTS-21 alleviates murine collagen-induced arthritis through inhibition of peripheral monocyte trafficking into the synovium

2023 · Xuelian Bai, Bin Zhou, et al. · International Immunopharmacology · 10

Clinical pharmacokinetics and pharmacodynamics of ongericimab: A potential long‐acting PCSK9 monoclonal antibody in healthy subjects and patients with hypercholesterolemia: Randomized, double‐blind, placebo‐controlled phase Ia and Ib/II studies

2024 · Juanjuan Jiang, Li Xu, et al. · Clinical and Translational Science · 9

Histological and Immune Responses Induced by pckA Gene Mutated Mycobacterium bovis BCG

2005 · Xuelian Bai · The Journal of Microbiology

Works count: 5

Citation count: 50

H-index: 4

I10-index: 3